Cargando…
Survival of Patients with Hepatitis B-Related Hepatocellular Carcinoma with Concomitant Metabolic Associated Fatty Liver Disease
PURPOSE: Metabolic associated fatty liver disease is a novel concept defined as fatty liver associated with metabolic disorders. We investigated the effect of metabolic associated fatty liver disease on hepatocellular carcinoma patient mortality. PATIENTS AND METHODS: A total of 624 patients with he...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10404410/ https://www.ncbi.nlm.nih.gov/pubmed/37551338 http://dx.doi.org/10.2147/DMSO.S416280 |
_version_ | 1785085292006342656 |
---|---|
author | You, Yajing Yang, Tao Wei, Shuhang Liu, Zongxin Liu, Chenxi Shen, Zijian Yang, Yinuo Feng, Yuemin Yao, Ping Zhu, Qiang |
author_facet | You, Yajing Yang, Tao Wei, Shuhang Liu, Zongxin Liu, Chenxi Shen, Zijian Yang, Yinuo Feng, Yuemin Yao, Ping Zhu, Qiang |
author_sort | You, Yajing |
collection | PubMed |
description | PURPOSE: Metabolic associated fatty liver disease is a novel concept defined as fatty liver associated with metabolic disorders. We investigated the effect of metabolic associated fatty liver disease on hepatocellular carcinoma patient mortality. PATIENTS AND METHODS: A total of 624 patients with hepatocellular carcinoma between 2012 and 2020 were enrolled in this retrospective study. Hepatic steatosis was diagnosed using computed tomography or magnetic resonance imaging. Metabolic associated fatty liver disease was defined based on the proposed criteria in 2020. Propensity score matching was performed for patients with metabolic associated fatty liver disease and those without the condition. A Cox proportional hazards regression model was used to evaluate the association between metabolic associated fatty liver disease and hepatocellular carcinoma patient outcomes. RESULTS: Patients with hepatocellular carcinoma and metabolic associated fatty liver disease tended to achieve better outcomes than did those without metabolic associated fatty liver disease after matching (p<0.001). Metabolic associated fatty liver disease was significantly associated with better prognosis in patients with concurrent hepatitis B infection (p<0.001). Moreover, high levels of hepatitis B viral DNA in serum samples was associated with a significantly increased risk of death in patients without non-metabolic associated fatty liver disease (p=0.045). Additionally, the association between metabolic associated fatty liver disease and survival in hepatitis B virus-related hepatocellular carcinoma was similar in all subgroups based on metabolic traits. CONCLUSION: Metabolic associated fatty liver disease increases the survival rate of patients with hepatocellular carcinoma and hepatitis B virus infection. The potential interaction of steatosis and virus replication should be considered for future research and clinical treatment strategies. |
format | Online Article Text |
id | pubmed-10404410 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Dove |
record_format | MEDLINE/PubMed |
spelling | pubmed-104044102023-08-07 Survival of Patients with Hepatitis B-Related Hepatocellular Carcinoma with Concomitant Metabolic Associated Fatty Liver Disease You, Yajing Yang, Tao Wei, Shuhang Liu, Zongxin Liu, Chenxi Shen, Zijian Yang, Yinuo Feng, Yuemin Yao, Ping Zhu, Qiang Diabetes Metab Syndr Obes Original Research PURPOSE: Metabolic associated fatty liver disease is a novel concept defined as fatty liver associated with metabolic disorders. We investigated the effect of metabolic associated fatty liver disease on hepatocellular carcinoma patient mortality. PATIENTS AND METHODS: A total of 624 patients with hepatocellular carcinoma between 2012 and 2020 were enrolled in this retrospective study. Hepatic steatosis was diagnosed using computed tomography or magnetic resonance imaging. Metabolic associated fatty liver disease was defined based on the proposed criteria in 2020. Propensity score matching was performed for patients with metabolic associated fatty liver disease and those without the condition. A Cox proportional hazards regression model was used to evaluate the association between metabolic associated fatty liver disease and hepatocellular carcinoma patient outcomes. RESULTS: Patients with hepatocellular carcinoma and metabolic associated fatty liver disease tended to achieve better outcomes than did those without metabolic associated fatty liver disease after matching (p<0.001). Metabolic associated fatty liver disease was significantly associated with better prognosis in patients with concurrent hepatitis B infection (p<0.001). Moreover, high levels of hepatitis B viral DNA in serum samples was associated with a significantly increased risk of death in patients without non-metabolic associated fatty liver disease (p=0.045). Additionally, the association between metabolic associated fatty liver disease and survival in hepatitis B virus-related hepatocellular carcinoma was similar in all subgroups based on metabolic traits. CONCLUSION: Metabolic associated fatty liver disease increases the survival rate of patients with hepatocellular carcinoma and hepatitis B virus infection. The potential interaction of steatosis and virus replication should be considered for future research and clinical treatment strategies. Dove 2023-08-02 /pmc/articles/PMC10404410/ /pubmed/37551338 http://dx.doi.org/10.2147/DMSO.S416280 Text en © 2023 You et al. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php). |
spellingShingle | Original Research You, Yajing Yang, Tao Wei, Shuhang Liu, Zongxin Liu, Chenxi Shen, Zijian Yang, Yinuo Feng, Yuemin Yao, Ping Zhu, Qiang Survival of Patients with Hepatitis B-Related Hepatocellular Carcinoma with Concomitant Metabolic Associated Fatty Liver Disease |
title | Survival of Patients with Hepatitis B-Related Hepatocellular Carcinoma with Concomitant Metabolic Associated Fatty Liver Disease |
title_full | Survival of Patients with Hepatitis B-Related Hepatocellular Carcinoma with Concomitant Metabolic Associated Fatty Liver Disease |
title_fullStr | Survival of Patients with Hepatitis B-Related Hepatocellular Carcinoma with Concomitant Metabolic Associated Fatty Liver Disease |
title_full_unstemmed | Survival of Patients with Hepatitis B-Related Hepatocellular Carcinoma with Concomitant Metabolic Associated Fatty Liver Disease |
title_short | Survival of Patients with Hepatitis B-Related Hepatocellular Carcinoma with Concomitant Metabolic Associated Fatty Liver Disease |
title_sort | survival of patients with hepatitis b-related hepatocellular carcinoma with concomitant metabolic associated fatty liver disease |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10404410/ https://www.ncbi.nlm.nih.gov/pubmed/37551338 http://dx.doi.org/10.2147/DMSO.S416280 |
work_keys_str_mv | AT youyajing survivalofpatientswithhepatitisbrelatedhepatocellularcarcinomawithconcomitantmetabolicassociatedfattyliverdisease AT yangtao survivalofpatientswithhepatitisbrelatedhepatocellularcarcinomawithconcomitantmetabolicassociatedfattyliverdisease AT weishuhang survivalofpatientswithhepatitisbrelatedhepatocellularcarcinomawithconcomitantmetabolicassociatedfattyliverdisease AT liuzongxin survivalofpatientswithhepatitisbrelatedhepatocellularcarcinomawithconcomitantmetabolicassociatedfattyliverdisease AT liuchenxi survivalofpatientswithhepatitisbrelatedhepatocellularcarcinomawithconcomitantmetabolicassociatedfattyliverdisease AT shenzijian survivalofpatientswithhepatitisbrelatedhepatocellularcarcinomawithconcomitantmetabolicassociatedfattyliverdisease AT yangyinuo survivalofpatientswithhepatitisbrelatedhepatocellularcarcinomawithconcomitantmetabolicassociatedfattyliverdisease AT fengyuemin survivalofpatientswithhepatitisbrelatedhepatocellularcarcinomawithconcomitantmetabolicassociatedfattyliverdisease AT yaoping survivalofpatientswithhepatitisbrelatedhepatocellularcarcinomawithconcomitantmetabolicassociatedfattyliverdisease AT zhuqiang survivalofpatientswithhepatitisbrelatedhepatocellularcarcinomawithconcomitantmetabolicassociatedfattyliverdisease |